Details of the Drug Combinations

General Information of This Drug (ID: DMH7W9X)

• Drug Name: SNDX-275 (DMH7W9X)
• Synonyms: Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Phase 3 [1]; Colorectal cancer; ICD 11: 2B91.Z; Status: Phase 2 [2]; Melanoma; ICD 11: 2C30; Status: Phase 2 [2]; Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Phase 2 [2]; Ovarian cancer; ICD 11: 2C73; Status: Phase 2 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

24 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-199 + SNDX-275	DCI7C9Q	ABT-199	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
BMS-754807 + SNDX-275	DCM4B1F	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
BMS-754807 + SNDX-275	DCJD5RX	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
CA4P + SNDX-275	DCNCZQN	CA4P	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Carfilzomib + SNDX-275	DCUIZT2	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Carfilzomib + SNDX-275	DCHG6DF	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Daporinad + SNDX-275	DC9E2W5	Daporinad	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Doxorubicin + SNDX-275	DCQZLBB	Doxorubicin	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Fostamatinib + SNDX-275	DC2HI8C	Fostamatinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
GDC-0980/RG7422 + SNDX-275	DCCI3LP	GDC-0980/RG7422	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Mitomycin + SNDX-275	DC8C7LW	Mitomycin	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
RTB101 + SNDX-275	DCSNU5R	RTB101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
RTB101 + SNDX-275	DCDBQM3	RTB101	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
SNDX-275 + Gefitinib	DCO838A	Gefitinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + THAPSIGARGIN	DCTAK3P	THAPSIGARGIN	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + Chloroxine	DCJ77B6	Chloroxine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + AS602868	DC0BLXA	AS602868	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + Tamoxifen	DCO8ME4	Tamoxifen	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + Mebendazole	DCP7UXP	Mebendazole	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + IMD-0354	DC1BZJP	IMD-0354	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
SNDX-275 + Mefloquine	DCPC8F8	Mefloquine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
THZ1 + SNDX-275	DCYY6UL	THZ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Trametinib + SNDX-275	DCA2KUI	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Trametinib + SNDX-275	DCTPW8M	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Erlotinib + SNDX-275	DC6ZL1I	Erlotinib	Non-Small-Cell Lung Carcinoma	[5]
Exemestane + SNDX-275	DCW9KXF	Exemestane	Breast Cancer	[6]
Olaparib + SNDX-275	DCIISCN	Olaparib	Fallopian Tube Cancer	[7]
SNDX-275 + Anastrozole	DCDIM5L	Anastrozole	Estrogen Receptor-negative Breast Cancer	[8]
SNDX-275 + Midazolam	DCEELVK	Midazolam	Drug Interaction	[9]
SNDX-275 + Capecitabine	DCXQ2KK	Capecitabine	Metastatic Breast Cancer	[10]
Fulvestrant + SNDX-275	DCVF159	Fulvestrant	Breast Cancer	[11]

References

• [1] ClinicalTrials.gov (NCT03538171) Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT00602030) Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
• [6] ClinicalTrials.gov (NCT00676663) Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
• [7] ClinicalTrials.gov (NCT03924245) Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
• [8] ClinicalTrials.gov (NCT01234532) Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
• [9] ClinicalTrials.gov (NCT03187015) A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
• [10] ClinicalTrials.gov (NCT03473639) A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
• [11] ClinicalTrials.gov (NCT02115594) Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer